Rare diseases have become an increasingly attractive target for pharmaceutical companies Canaccord’s Dr Shane Storey says there are strong incentives for companies to develop therapies for rare ...

Rising demand and supply risks are setting the stage for a wave of ASX copper stocks positioning for the next potential growth cycle. This powerful rally was partially driven by short-term factors ...

Data centers were two-thirds of Goodman’s (ASX.GMG) $14.5 billion development pipeline at the end of March 2026, and the group remains committed to expanding it to $18 billion by June 2026. Management ...

But within that slowdown sits a clear opportunity - the rapid rise of low and no alcohol (NoLo) beverages. For listed players, it’s becoming a necessary pivot. For challengers, it’s a chance to build ...